top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MeiraGTx Holdings plc - Ordinary Shares (NQ:MGTX)

10.65 +0.65 (+6.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,288,661
Open 10.03
Bid (Size) 10.65 (100)
Ask (Size) 11.25 (100)
Prev. Close 10.00
Today's Range 9.920 - 10.71
52wk Range 5.020 - 11.85
Shares Outstanding 80,479,684
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Reports First Quarter 2026 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire

Performance

YTD
+36.4%
+36.4%
1 Month
+19.0%
+19.0%
3 Month
+40.9%
+40.9%
6 Month
+28.3%
+28.3%
1 Year
+98.7%
+98.7%

More News

Read More
MeiraGTx Holdings (NASDAQ:MGTX) Passes Minervini Trend Template and High Growth Momentum Screen ↗
Via Chartmill
News headline image
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
From MeiraGTx
Via GlobeNewswire
MGTX Stock Soared 13% Today – What’s The Eli Lilly Angle? ↗
Via Stocktwits
News headline image
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
Via Investor Brand Network
Topics Intellectual Property
News headline image
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
From BioMedWire
Via GlobeNewswire
News headline image
The Biotech Tug-of-War: Is Kiora Pharmaceuticals Positioned to Ride the 2025 Commodity Wave?
Via MarketMinute
Topics Derivatives Economy Intellectual Property
News headline image
MeiraGTx Reports Third Quarter 2025 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
News headline image
Eli Lilly Expands Genetic Eye-Disease Focused Pipeline With MeiraGTx Gene Therapy Collaboration ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Sales Jump 1,133 Percent ↗
Via The Motley Fool
News headline image
MeiraGTx Reports Second Quarter 2025 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
News headline image
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
Via Benzinga
News headline image
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Reports First Quarter 2025 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
News headline image
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
From MeiraGTx
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill

Frequently Asked Questions

Is MeiraGTx Holdings plc - Ordinary Shares publicly traded?
Yes, MeiraGTx Holdings plc - Ordinary Shares is publicly traded.
What exchange does MeiraGTx Holdings plc - Ordinary Shares trade on?
MeiraGTx Holdings plc - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for MeiraGTx Holdings plc - Ordinary Shares?
The ticker symbol for MeiraGTx Holdings plc - Ordinary Shares is MGTX on the Nasdaq Stock Market
What is the current price of MeiraGTx Holdings plc - Ordinary Shares?
The current price of MeiraGTx Holdings plc - Ordinary Shares is 10.65
When was MeiraGTx Holdings plc - Ordinary Shares last traded?
The last trade of MeiraGTx Holdings plc - Ordinary Shares was at 05/29/26 04:00 PM ET
What is the market capitalization of MeiraGTx Holdings plc - Ordinary Shares?
The market capitalization of MeiraGTx Holdings plc - Ordinary Shares is 857.11M
How many shares of MeiraGTx Holdings plc - Ordinary Shares are outstanding?
MeiraGTx Holdings plc - Ordinary Shares has 857M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page